CN114423457A - 治疗脾肿大的方法 - Google Patents

治疗脾肿大的方法 Download PDF

Info

Publication number
CN114423457A
CN114423457A CN202180004918.1A CN202180004918A CN114423457A CN 114423457 A CN114423457 A CN 114423457A CN 202180004918 A CN202180004918 A CN 202180004918A CN 114423457 A CN114423457 A CN 114423457A
Authority
CN
China
Prior art keywords
weeks
bid
myelofibrosis
human subject
btk inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180004918.1A
Other languages
English (en)
Chinese (zh)
Inventor
W·P·罗特鲍姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thalios Pharmaceuticals
Original Assignee
Thalios Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thalios Pharmaceuticals filed Critical Thalios Pharmaceuticals
Publication of CN114423457A publication Critical patent/CN114423457A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Solid Wastes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
CN202180004918.1A 2020-01-08 2021-01-08 治疗脾肿大的方法 Pending CN114423457A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062958632P 2020-01-08 2020-01-08
US62/958632 2020-01-08
PCT/US2021/012696 WO2021142257A1 (en) 2020-01-08 2021-01-08 Methods of treating splenomegaly

Publications (1)

Publication Number Publication Date
CN114423457A true CN114423457A (zh) 2022-04-29

Family

ID=76788747

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180004918.1A Pending CN114423457A (zh) 2020-01-08 2021-01-08 治疗脾肿大的方法

Country Status (15)

Country Link
EP (2) EP3980069A4 (https=)
JP (2) JP7771064B2 (https=)
KR (1) KR20220130151A (https=)
CN (1) CN114423457A (https=)
AU (1) AU2021205484A1 (https=)
BR (1) BR112022013646A2 (https=)
CA (1) CA3164063A1 (https=)
CO (1) CO2022010592A2 (https=)
CR (1) CR20220374A (https=)
IL (1) IL294582A (https=)
JO (1) JOP20220168A1 (https=)
MA (3) MA63848B1 (https=)
MX (1) MX2022008490A (https=)
TN (1) TN2022000185A1 (https=)
WO (1) WO2021142257A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY
US20240024314A1 (en) 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
IL309238A (en) * 2021-06-16 2024-02-01 Telios Pharma Inc Treatment of symptoms associated with myeloproliferative tumors
WO2023071973A1 (en) * 2021-10-26 2023-05-04 Shenzhen Targetrx, Inc. Fused bicyclic compound for inhibiting activity of tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
WO2016054491A1 (en) * 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN112313214A (zh) * 2018-06-19 2021-02-02 默克专利有限公司 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法
CN109942835A (zh) * 2019-03-27 2019-06-28 广州楹鼎生物科技有限公司 一种催化分解木质纤维原料的方法
TW202128156A (zh) * 2019-11-14 2021-08-01 美商夸格智財控股有限公司 用於癌症治療之btk抑制劑及mdm2抑制劑之組合
EP3980069A4 (en) * 2020-01-08 2022-08-17 Telios Pharma, Inc. METHODS OF TREATMENT OF SPLENOMEGALY

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041614A1 (en) * 2022-08-25 2024-02-29 Beigene Switzerland Gmbh Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof

Also Published As

Publication number Publication date
EP4000624A1 (en) 2022-05-25
AU2021205484A1 (en) 2022-08-18
JP2026027353A (ja) 2026-02-18
MA57226B1 (fr) 2023-06-28
CR20220374A (es) 2023-01-25
MA57226A1 (fr) 2023-02-28
EP3980069A1 (en) 2022-04-13
JOP20220168A1 (ar) 2023-01-30
CO2022010592A2 (es) 2022-10-31
MX2022008490A (es) 2022-10-13
MA63848A1 (fr) 2024-04-30
JP2023509968A (ja) 2023-03-10
MA63848B1 (fr) 2024-10-31
TN2022000185A1 (en) 2024-04-01
MA69153A1 (fr) 2025-07-31
KR20220130151A (ko) 2022-09-26
CA3164063A1 (en) 2021-07-15
WO2021142257A1 (en) 2021-07-15
JP7771064B2 (ja) 2025-11-17
BR112022013646A2 (pt) 2022-10-04
IL294582A (en) 2022-09-01
EP3980069A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
AU2021225157B2 (en) Combination therapy of tetracyclic quinolone analogs for treating cancer
CN114423457A (zh) 治疗脾肿大的方法
JP2023182577A (ja) 化学療法計画中の免疫応答の保護
JP2025072429A (ja) 骨髄増殖性腫瘍を治療する方法
TWI741286B (zh) 治療癌症之方法
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
KR20220101122A (ko) 암 치료를 위한 btk 억제제와 mdm2 억제제의 병용물
US11642343B2 (en) Methods of treating splenomegaly
US20240293403A1 (en) Treatment of Symptoms Associated with Myeloproliferative Neoplasms
KR20250151363A (ko) 골수증식성 신생물의 치료 방법
HK40078282A (en) Btk inhibitors for treating splenomegaly
US20250387383A1 (en) Methods of treating myeloproliferative neoplasms
JP2004530700A (ja) Ａ１アデノシン及びｐ２ｘプリン受容体拮抗薬を使用する方法及び製剤
HK40112620A (zh) 喹唑啉酮化合物用於治疗癌症的新用途
HK40107174A (zh) 化疗方案期间免疫反应的保持
EA045240B1 (ru) Способы лечения рака

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination